Johnson & Johnson Innovation - JJDC
Latest statistics and disclosures from Johnson & Johnson Innovation - JJDC's latest quarterly 13F-HR filing:
- Top 5 stock holdings are FATE, ARWR, PTGX, CVRX, LEGN, and represent 85.67% of Johnson & Johnson Innovation - JJDC's stock portfolio.
- Added to shares of these 4 stocks: CVRX (+$98M), Therapeutics Acquisition Cor (+$10M), NPCE, Zymergen.
- Started 4 new stock positions in Zymergen, NPCE, Therapeutics Acquisition Cor, CVRX.
- Reduced shares in these 1 stock: SENS.
- Johnson & Johnson Innovation - JJDC was a net buyer of stock by $108M.
- Johnson & Johnson Innovation - JJDC has $978M in assets under management (AUM), dropping by 26.69%.
- Central Index Key (CIK): 0000924020
Tip: Access up to 7 years of quarterly data
Positions held by Johnson & Johnson Innovation - JJDC consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Johnson & Johnson Innovation - JJDC
Johnson & Johnson Innovation - JJDC holds 21 positions in its portfolio as reported in the June 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Fate Therapeutics (FATE) | 30.0 | $293M | 3.4M | 86.79 |
|
|
| Arrowhead Pharmaceuticals (ARWR) | 27.6 | $270M | 3.3M | 82.82 |
|
|
| Protagonist Therapeutics (PTGX) | 11.2 | $110M | 2.4M | 44.88 |
|
|
| CVRX (CVRX) | 10.0 | $98M | NEW | 3.5M | 28.00 |
|
| Legend Biotech Corporation Sponsored Ads (LEGN) | 6.8 | $67M | 1.6M | 41.05 |
|
|
| Meiragtx Holdings (MGTX) | 4.6 | $45M | 2.9M | 15.50 |
|
|
| Fusion Pharmaceuticals | 3.0 | $30M | 3.7M | 8.08 |
|
|
| Vor Biopharma (VOR) | 2.0 | $20M | 1.1M | 18.65 |
|
|
| Chardan Healthcare Acqu- Ord (PHGE) | 1.2 | $12M | 2.1M | 5.46 |
|
|
| Therapeutics Acquisition Cor Com Cl A | 1.1 | $10M | NEW | 1.0M | 10.27 |
|
| Adicet Bio (ACET) | 0.8 | $7.5M | 729k | 10.29 |
|
|
| Phasebio Pharmaceuticals | 0.6 | $6.0M | 1.6M | 3.72 |
|
|
| Aldeyra Therapeutics (ALDX) | 0.5 | $4.5M | 395k | 11.33 |
|
|
| Castlight Health CL B | 0.2 | $2.1M | 811k | 2.63 |
|
|
| Neuropace (NPCE) | 0.1 | $1.3M | NEW | 55k | 23.79 |
|
| Zymergen | 0.1 | $662k | NEW | 17k | 39.99 |
|
| Tracon Pharmaceuticals | 0.1 | $545k | 84k | 6.49 |
|
|
| Catalyst Biosciences | 0.0 | $290k | 67k | 4.33 |
|
|
| Graybug Vision Com Shs | 0.0 | $269k | 50k | 5.43 |
|
|
| Pulmonx Corp (LUNG) | 0.0 | $249k | 5.6k | 44.16 |
|
|
| Senseonics Hldgs (SENS) | 0.0 | $210k | -88% | 55k | 3.84 |
|
Past Filings by Johnson & Johnson Innovation - JJDC
SEC 13F filings are viewable for Johnson & Johnson Innovation - JJDC going back to 2019
- Johnson & Johnson Innovation - JJDC 2021 Q2 filed Aug. 3, 2021
- Johnson & Johnson Innovation - JJDC 2021 Q1 filed May 6, 2021
- Johnson & Johnson Innovation - JJDC 2020 Q4 filed Feb. 9, 2021
- Johnson & Johnson Innovation - JJDC 2020 Q3 filed Nov. 3, 2020
- Johnson & Johnson Innovation - JJDC 2020 Q2 filed Aug. 12, 2020
- Johnson & Johnson Innovation - JJDC 2020 Q1 filed May 13, 2020
- Johnson & Johnson Innovation - JJDC 2019 Q4 filed Feb. 14, 2020